Associated tags: Animal, Bacteria, Plant, RNA, Human, Biology, Oxford Nanopore Technologies, Virus, DNA, Cancer, Molecular biology, Research, Genetics, Health, Nanopore sequencing, Biotechnology, Science, Genomics, Antibiotics, Health Technology
Locations: SWITZERLAND, MINNESOTA, FRANCE, CANADA, MIDDLE EAST, US, ASIA, NETHERLANDS, ITALY, HAWAII, NEW YORK, EUROPE, UNITED STATES, UNITED KINGDOM, NORTH AMERICA, USA, JAPAN
Health Technology,
Technology,
Nanotechnology,
Pharmaceutical,
Oncology,
Professional Services,
Genetics,
Artificial Intelligence,
Clinical Trials,
Science,
Biotechnology,
Software,
Data Analytics,
Health,
Research,
WGS,
Nephrology,
APHP,
STR,
Single-nucleotide polymorphism,
Partnership,
CFH,
Patient,
Chelsea Handler,
RUO,
HPO,
Oxford Nanopore Technologies,
Thrombotic microangiopathy,
Developed country,
Nanopore sequencing,
Thrombosis,
CNV,
Pharmaceutical industry Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
Key Points:
- Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
- It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
- In the future, the collaboration will deliver other variant interpretation applications addressing the needs of cancer predisposition and somatic analysis.
- “We are excited to collaborate with SeqOne to provide end-to-end solutions for our customers in rare disease and oncology.
Health,
Genetics,
Other Science,
General Health,
Research,
Science,
Love,
A-DNA,
Oxford Nanopore Technologies,
NetBurst (microarchitecture),
P2i,
Animal,
Plant,
RNA,
Early access,
Nanopore sequencing,
DNA,
Video game Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range.
Key Points:
- Oxford Nanopore Technologies today announced the early access launch of its all-in-one desk top sequencing device, the PromethION 2 Integrated (P2i) to complete its PromethION product range.
- Each flow cell will be capable of delivering the lowest price per Gb for Oxford Nanopore sequencing, providing a rapid and convenient solution for achieving the coverage required for sequencing larger genomes.
- Since being rolled out in beta access in November 2023, several institutions have put the device to the test with remarkable success.
- “With the launch of the P2i, Oxford Nanopore is heralding a new era of sequencing technology, offering a fully integrated, plug-and-play device that opens up unparalleled possibilities in both research and applied markets.
Retrieved on:
Wednesday, November 29, 2023
Research,
Technology,
Nanotechnology,
Other Natural Resources,
Food,
Beverage,
Agriculture,
Retail,
Natural Resources,
Science,
Other Science,
Safety,
Shellfish,
DNA,
Plant,
Oxford Nanopore Technologies,
Accreditation,
Meat,
Workflow,
Food industry,
Food safety,
Partnership,
Nanopore sequencing,
Pharmaceutical industry,
Medical device This partnership aims to develop and commercialise a validated, fit-for-purpose test using Oxford Nanopore-based sequencing to identify multiple species present in different food sample types, including unprocessed, highly processed or complex.
Key Points:
- This partnership aims to develop and commercialise a validated, fit-for-purpose test using Oxford Nanopore-based sequencing to identify multiple species present in different food sample types, including unprocessed, highly processed or complex.
- As experts in food authenticity testing with a track record for innovation, WeNou compared nanopore sequencing with the traditional sequencing workflow commonly used in the food industry.
- The collaboration will expand on the preliminary study by optimising the workflow using the latest sequencing chemistry from Oxford Nanopore.
- After validation, the test will be suitable for service providers to obtain industry accreditation to assess food and feed authenticity.
Retrieved on:
Tuesday, October 31, 2023
Technology,
Research,
Genetics,
Nanotechnology,
Health Technology,
Biotechnology,
Health,
Science,
Artificial Intelligence,
McDonnell Genome Institute,
Colab,
Genomics,
DSM-IV codes,
Oxford Nanopore Technologies,
Textile,
Genetic disorder,
Genetic distance,
Nanopore sequencing,
Data,
Doctor of Philosophy,
Society,
Disease,
Partnership,
NICU,
Shriners,
Cancer,
Patient,
Diagnosis,
Cardiovascular disease,
Antibiotics It is estimated that roughly 2.8 million children in the US reported a rare genetic disorder, according to data from the National Survey of Children’s Health .
Key Points:
- It is estimated that roughly 2.8 million children in the US reported a rare genetic disorder, according to data from the National Survey of Children’s Health .
- "For this incredibly high-risk patient population, speed and data-rich insights matter,” said Gordon Sanghera, PhD, CEO of Oxford Nanopore Technologies.
- Fabric Genomics and Rady Children’s Institute for Genomic Medicine have published results showing Fabric AI GEM to predict causative variants in genomes from previously diagnosed newborns and rare disease patients.
- In addition, the partners will launch early customer availability at the meeting and showcase a workflow integration at Fabric Genomic’s booth #1215 on Friday November 3rd at 1 p.m.
Retrieved on:
Wednesday, October 25, 2023
Health Technology,
Data Management,
Other Health,
Technology,
Nanotechnology,
Apps,
Applications,
Biometrics,
Medical Devices,
Genetics,
Other Technology,
Biotechnology,
Science,
Software,
Other Science,
Research,
Health,
ASHG,
Data analysis,
Genomics,
Oxford Nanopore Technologies,
IVD,
Nanopore sequencing,
Society,
Learning,
Structural variation in the human genome,
Partnership,
Classification,
Cancer,
Medical device,
Medical imaging Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Saphetor, the next generation sequencing data analysis company, today announce a new partnership to support the comprehensive analysis of nanopore sequencing data and to enable end-to-end workflows.
Key Points:
- Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Saphetor, the next generation sequencing data analysis company, today announce a new partnership to support the comprehensive analysis of nanopore sequencing data and to enable end-to-end workflows.
- The collaboration with Saphetor will enable a direct connection between secondary and tertiary analysis, connecting Oxford Nanopore EPI2ME™ research software with VarSome Clinical, a CE-marked IVD medical device and HIPAA-compliant platform from Saphetor.
- Oxford Nanopore’s sequencing platform currently offers research tools to make sense of raw sequencing signal and offer initial analysis, including basecalling.
- The partnership with Saphetor will offer another layer of tertiary analysis focused on genetic variants and the prioritisation of those likely linked to conditions.
Retrieved on:
Thursday, October 19, 2023
Research,
General Health,
Oncology,
Biometrics,
Technology,
Genetics,
Health Technology,
Science,
Nanotechnology,
Biotechnology,
Other Science,
Health,
Mayo,
Pathology,
Medical laboratory,
Oxford Nanopore Technologies,
Nanopore,
Methylation,
Cancer,
Patient,
Mayo Clinic,
Nanopore sequencing,
DNA,
Pharmaceutical industry Mayo Clinic and Oxford Nanopore have identified several areas of development, spanning a wide breadth of applications from translational research in human genetics to detection of genetic predisposition to cancer.
Key Points:
- Mayo Clinic and Oxford Nanopore have identified several areas of development, spanning a wide breadth of applications from translational research in human genetics to detection of genetic predisposition to cancer.
- “We are proud to work with Mayo Clinic to support the development of new tests that will assist clinical decision-making and improve patient lives.
- Nanopore sequencing is well positioned to serve Mayo Clinic’s goals of improving testing in some of the hardest-to-characterize conditions.
- “Pairing Oxford Nanopore’s innovative nanopore sequencing with Mayo Clinic’s world-class clinical and diagnostic testing knowledge further helps advance patient care,” says Bobbi Pritt, M.D.
Retrieved on:
Thursday, September 21, 2023
University,
Biotechnology,
Education,
Technology,
Health,
General Health,
Pharmaceutical,
Research,
Infectious Diseases,
Nanotechnology,
Science,
Partnership,
Therapy,
COVID-19,
AIBN,
Nature Communications,
Attention,
Cell,
RNA,
Nanopore sequencing,
Messenger,
BASE,
Oxford Nanopore Technologies,
Quality control,
Biological engineering,
University of Queensland,
Pharmaceutical industry,
Vaccine Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.
Key Points:
- Researchers at The University of Queensland are harnessing the latest sequencing technology developed by UK-based biotech Oxford Nanopore Technologies to analyse mRNA vaccines and therapies.
- BASE researchers showed how nanopore sequencing can analyse the quality of mRNA vaccines and therapies, in a study published today in Nature Communications .
- Crucially, Dr Gunter said in the future, mRNA vaccines could be analysed in real-time, providing testing within hours of mRNA manufacture so quality control issues could be quickly detected.
- "We are excited to partner with the BASE team at The University of Queensland to further research supporting the manufacture and quality control of mRNA vaccines and therapies,” said Gordon Sanghera, CEO of Oxford Nanopore.
Retrieved on:
Tuesday, September 19, 2023
Research,
Mental Health,
Technology,
Genetics,
Health Technology,
Software,
Health,
Data Management,
Science,
Oncology,
CARD,
Genetic variation,
Methylation,
Alcohol-related dementia,
University,
Nature Methods,
Alzheimer's disease,
Oxford,
Dementia,
Bangladesh Technical Education Board,
SV,
Chemistry,
National Cancer Institute,
Oxford Nanopore Technologies,
HIV disease progression rates,
R10,
SNP,
NIH,
Genome,
Disease,
Fine chemical,
Medical imaging,
Antibiotics The study protocol is currently being used to sequence thousands of brain-based human genomes as a part of the NIH CARD initiative.
Key Points:
- The study protocol is currently being used to sequence thousands of brain-based human genomes as a part of the NIH CARD initiative.
- The methylation data is produced during a standard sequencing run and not as the result of a separate process.
- Combined with the latest chemistry, Kit 14 and R10.4.1 flow cells, Oxford Nanopore now delivers the most complete and accurate genomic data, at scale.
- “We are delighted to see this latest work from the NIH CARD team, whose approach demonstrates breakthrough accuracy with Oxford Nanopore’s newest Q20+ chemistry and the R10 nanopore, whilst using the same device.
Retrieved on:
Thursday, August 24, 2023
Other Education,
Education,
North Central High School,
Science,
DNA,
Oxford Nanopore Technologies,
Genetics,
SARS-CoV-2,
University,
Nanopore sequencing,
Biodiversity,
School,
Student,
Biology,
Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York,
Tutoring,
Forestry,
Cold Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of “Education beta”, its pilot education programme and the first of its kind in the world delivering nanopore sequencing into the global education sector, with the aim to increase life science literacy for the next generation.
Key Points:
- Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of “Education beta”, its pilot education programme and the first of its kind in the world delivering nanopore sequencing into the global education sector, with the aim to increase life science literacy for the next generation.
- The pilot will include up to 50 scientists wishing to use sequencing for scientific education in high school or undergraduate settings.
- In addition, a collaboration has been agreed between Oxford Nanopore and the Cold Spring Harbor Laboratory DNA Learning Center (DNALC) for the development of accessible educational infrastructure that has the potential to make in-classroom DNA sequencing routine for university and pre-university educators.
- Cold Spring Harbor Laboratory is proud to work with Oxford Nanopore to meet this challenge.”
This agreement comes alongside the launch of Education Beta from Oxford Nanopore, a new programme designed to enable and amplify the efforts of educators in the existing nanopore sequencing community.
Technology,
Genetics,
Nanotechnology,
Clinical Trials,
Health Technology,
Software,
Biotechnology,
Health,
Artificial Intelligence,
Partnership,
Classification,
Multimedia,
Research,
Nanopore sequencing,
Oxford Nanopore Technologies,
Hospital,
Data analysis,
Patient,
Pilot Project on Children used by adults in the commission of crime,
Rare,
Antibiotics,
Medical imaging Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data.
Key Points:
- Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data.
- The advanced platform will seamlessly empower clinical centres including hospitals, genetic labs and researchers with human whole-genome sequencing data and analysis.
- The platform will seamlessly integrate with EPI2ME™, Oxford Nanopore’s data analysis solution, which will perform the secondary sequence analysis.
- “We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data.
